Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAE124
- Development stage
- Preclinical
- Lead developer
- Laekna
01
Overview
LAE124 is a preclinical drug candidate developed by Laekna for the treatment of obesity. It targets the amylin pathway, which is involved in the regulation of energy balance and glucose metabolism. Amylin is a hormone co-secreted with insulin that acts on the central nervous system to promote satiety and slow gastric emptying. By modulating this pathway, LAE124 aims to reduce appetite and body weight.
02
Targets
AMY receptor (Calcitonin receptor (with ramps))CALCR (Calcitonin receptor)
Beyond the preview
Go deeper on LAE124.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAE124.